Fresenius Medical Care stock eases as Q2 2026 profit jump meets cautious valuation
Published on 09/02/2026 at 08:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care stock (ISIN DE0005785802) last closed on Xetra at 39.92 EUR as of August 29, 2026, leaving the German dialysis specialist trading below its level at the start of 2026 despite a clear profit jump in the second quarter of 2026 according to recent market data.
Q2 2026 earnings show profit jump
According to a same-day European equities overview summarized in a recent analysis of Fresenius Medical Care, the company reported a clear profit increase in the second quarter of 2026, with earnings rising above market expectations for that period.
The Q2 2026 reporting period falls well within the current freshness window for fundamentals relative to September 2, 2026, making this profit jump and earnings beat central to the current investment narrative for Fresenius Medical Care.
Valuation and price action on Xetra
Market data compiled in a detailed Xetra-based review shows that Fresenius Medical Care stock closed at 39.92 EUR on Xetra on August 29, 2026, while an additional European quote overview for the same date records a derived price of 39.39 EUR, a daily loss of 1.33 percent and trading volume of 116,340 shares.
The same market overview notes that the 39.92 EUR closing price on August 29, 2026 keeps Fresenius Medical Care shares below their level at the beginning of 2026, even after the Q2 2026 profit jump, highlighting a quantified gap between improved earnings and the share price response.
Further figures and background on Fresenius Medical Care
Investors can find more detailed data and news on Fresenius Medical Care via the Ad-Hoc News overview and the company's investor relations materials.
Dialysis services as core business
Fresenius Medical Care focuses on dialysis services and related products for patients with chronic kidney failure, making it one of the major global providers in this niche healthcare segment.
The company generates a significant portion of its revenue from long term treatment contracts and dialysis consumables, so sustained profit growth in Q2 2026 suggests that operational trends in its core business remained favorable through mid 2026.
Stock level and investor takeaway
Based on recent Xetra data, Fresenius Medical Care stock closed at 39.92 EUR on August 29, 2026, with an additional European quote snapshot for that date indicating a price of 39.39 EUR and a daily decline of 1.33 percent, leaving the stock still below its early 2026 level despite the Q2 2026 profit jump.
Fresenius Medical Care at a glance
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra
- Price (as of August 29, 2026): 39.92 EUR
- Market capitalization: [value] EUR (as of August 29, 2026)
- Sector / Industry: Healthcare / Medical Services
- Index membership: DAX
